:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Author:	Iskandar Idris
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Diabetes, Obesity and Metabolism Now
Online Access:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1002/doi2.90
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
by: Iskandar Idris
Published: (2024)

Epigenetic changes shown to cause type 2 diabetes
by: Iskandar Idris
Published: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
by: Iskandar Idris
Published: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
by: Iskandar Idris
Published: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
by: Iskandar Idris
Published: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
by: Iskandar Idris
Published: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
by: Iskandar Idris
Published: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
by: Iskandar Idris
Published: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
by: Iskandar Idris
Published: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
by: Iskandar Idris
Published: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
by: Iskandar Idris
Published: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
by: Iskandar Idris
Published: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
by: Iskandar Idris
Published: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
by: Iskandar Idris
Published: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
by: Iskandar Idris
Published: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
by: Iskandar Idris
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

The latest evidence and clinical guidelines for use of meal replacements in very‐low‐calorie diets or low‐calorie diets for the treatment of obesity
by: Shenelle A. Edwards‐Hampton, et al.
Published: (2024)

Impact of a very low‐calorie ketogenic diet on metabolic and microbiota outcomes in post‐bariatric patients and bariatric‐Naïve individuals: A comparative pilot study
by: Ilaria Ernesti, et al.
Published: (2025)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
by: Iskandar Idris, et al.
Published: (2025)

Low‐calorie, high‐protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity
by: Carmen Rodrigo‐Carbó, et al.
Published: (2024)

Partial remission of type 1 diabetes: Do immunometabolic events define the honeymoon period?
by: J. Jason Collier, et al.
Published: (2025)

Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real‐world evidence from a 22‐year follow‐up study
by: Abhilasha Akerkar, et al.
Published: (2025)

Progression of cardiac dysfunction in patients with type 2 diabetes without overt cardiovascular disease: A three‐year follow‐up echocardiographic study ( DIACAR )
by: Yara Antakly Hanon, et al.
Published: (2025)

Impact of caloric restriction on diabetes remission in Korean adults with obesity (CREDO‐K study)
by: Mee Kyoung Kim, et al.
Published: (2025)

An internet‐based platform with a low‐calorie dietary intervention improves cardiometabolic risk factors in overweight and obese people in China: Half‐year follow‐up results of a randomized controlled trial
by: Yang Zhong, et al.
Published: (2024)

Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial
by: Joanna Y. Gong, et al.
Published: (2025)

Validation of the Individualized Metabolic Surgery score in predicting long‐term remission of diabetes after duodenal switch‐type procedures
by: Sultan Almuallem, et al.
Published: (2024)

Single‐cell transcriptional profiling reveals cellular senescence and inflammatory persistence as key features of type 1 diabetes partial remission
by: Ruiqiang Xie, et al.
Published: (2025)

Effect of insulin sensitivity, insulin secretion, and beta cell function on the remission of type 2 diabetes: A post hoc analysis of the IDEATE trial
by: Xianglin Wu, et al.
Published: (2025)

Associations of a proinflammatory diet, habitual salt intake, and the onset of type 2 diabetes: A prospective cohort study from the UK Biobank
by: Wenqi Shen, et al.
Published: (2024)